Amspro Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.90 Cr
as on 02-07-2024
- Paid Up Capital ₹ 1.90 Cr
as on 02-07-2024
- Company Age 9 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.55 Cr
as on 02-07-2024
- Revenue 20.54%
(FY 2022)
- Profit 163.50%
(FY 2022)
- Ebitda 0.52%
(FY 2022)
- Net Worth 5.08%
(FY 2022)
- Total Assets 6.95%
(FY 2022)
About Amspro Lifesciences
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.90 Cr and a paid-up capital of Rs 1.90 Cr.
The company currently has active open charges totaling ₹4.55 Cr.
Katepalli Sunita and Minnekanti Babu serve as directors at the Company.
- CIN/LLPIN
U24100TG2015PTC098176
- Company No.
098176
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Mar 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Amspro Lifesciences Private Limited offer?
Amspro Lifesciences Private Limited offers a wide range of products and services, including Fish Foods, Aqua Probiotics.
Who are the key members and board of directors at Amspro Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Katepalli Sunita  | Director | 26-Mar-2015 | Current |
| Minnekanti Babu | Director | 26-Mar-2015 | Current |
Financial Performance of Amspro Lifesciences.
Amspro Lifesciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 20.54% increase. The company also saw a substantial improvement in profitability, with a 163.5% increase in profit. The company's net worth moved up by a moderate rise of 5.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Amspro Lifesciences?
In 2022, Amspro Lifesciences had a public holding of 40.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Amspro Biotech Private LimitedActive 14 years 4 monthsKatepalli Sunita and Minnekanti Babu are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 31 Jan 2023 | ₹7.50 M | Open |
Others Creation Date: 06 May 2017 | ₹3.80 Cr | Open |
How Many Employees Work at Amspro Lifesciences?
Amspro Lifesciences has a workforce of 18 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Amspro Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Amspro Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
